Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 Enero 2024 - 7:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer,
is scheduled to present at the 42nd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 9, 2024 at 7:30 a.m. Pacific Time at
the Westin St. Francis Hotel in San Francisco.
Interested parties may access the live webcast of this
presentation by visiting the Investors & Media section of
Pliant’s website at www.PliantRx.com. The replay of this
webcast will be archived for 30 days following the conclusion of
the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical
company and leader in the discovery and development of novel
therapeutics for the treatment of fibrotic diseases. Pliant's lead
product candidate, bexotegrast (PLN-74809), is an oral, small
molecule, dual selective inhibitor of αvß6 and αvß1 integrins that
is in development in the lead indications for the treatment of
idiopathic pulmonary fibrosis, or IPF, and primary sclerosing
cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical-stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social media X,
LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Gráfica de Acción Histórica
De May 2023 a May 2024